Yet another RCT has found that Paxlovid has failed to significantly improve its clinical endpoint. STOP-PASC, a double blind placebo controlled RCT (n = 155) published in the Journal of the American Medical Association, found that a 15 days course of 300 mg nirmatrelvir and 100 mg ritonavir (the drugs constituting Paxlovid) taken twice daily with patients followed up until 15 weeks after randomization (n = 102) made no statistically significant difference in improvements of core symptoms, except for brain fog, compared to the placebo-ritonavir combo given a similar dose twice daily over the same period of time (n = 53).
‘Total summative severity scores for all core symptoms at 5, 10, and 15 weeks were similar between the intervention and control groups……the difference between groups for the change in severity scores across 15 weeks was statistically significant for brain fog only.’
There was also no statistically significant difference between groups in the total number of post-randomization weeks in which patients experienced mild or no symptoms for each core symptom adjusted to baseline symptom severity except for brain fog. Patients in the intervention arm suffered 4 SAEs while there was only 1 SAE in the control arm.
As I mentioned in a post from June, Pfraudlovid also failed to reduce 28 day COVID mortality rate in the RECOVERY trial and another RCT published in the New England Journal of Medicine, found that Pfraudlovid only reduced the median time to sustained alleviation of all signs and symptoms by one day less than the standard of care group which is not a statistically significant or clinically meaningful improvement over the standard of care. Despite these abysmal experimental results, Pfraudster charges up to $1400 per 5 day course for this ineffective garbage while medicare and medicaid (your tax dollars) continues to spend millions of dollars on it.